Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310253 | 0.86 | MAPK14 (0.49) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL2398076 | 0.84 | MAPK14 (0.47) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL2390837 | 0.83 | MAPK14 (0.46) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL1725524 | 0.83 | MAPK14 (0.46) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL1722735 | 0.82 | MAPK14 (0.51) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL2390696 | 0.82 | MAPK14 (0.45) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL2394658 | 0.82 | MAPK14 (0.45) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL1728728 | 0.81 | MAPK14 (0.44) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL2390786 | 0.80 | MAPK14 (0.43) | MAPK14CYP2C9MAPK13 | |
| SCHEMBL2390789 | 0.79 | MAPK14 (0.42) | MAPK14CYP2C9MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8012980-B2 | Isoquinolinone derivatives | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099665-A1 | ISOQUINOLINONE DERIVATIVES | SDHA, NQO1, CYP3A5 | MAPK14 3792/4885CYP2C9 98/4885MAPK13 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.